NEW YORK – Aspira Womens Health (formerly Vermillion) reported after the close of the market on Thursday flat third quarter revenues year over year.
For the three months ended Sept. 30, the Austin, Texas-based cancer diagnostics firm said that total revenues fell to $1.2 million from $1.3 million in the year-ago quarter. Product revenues were $1.2 million, flat compared to Q3 2019. The company had no service revenues. It posted $44,000 in services revenues in Q3 2019 but shut down it services business that quarter.